Quantitative chiral and achiral determination of ketamine and its metabolites by LC–MS/MS in human serum, urine and fecal samples

Journal of Pharmaceutical and Biomedical Analysis

Volumn 139, Issue , 2017, Pages 87-97

  Hasan, Mahmoud ^a   Hofstetter, Robert ^b   Fassauer, Georg M ^b   Link, Andreas ^b   Siegmund, Werner ^a   Oswald, Stefan ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Chiral; Dehydronorketamine; Hydroxynorketamine; Ketamine; LC MS MS; Norketamine

Indexed keywords

2 PROPANOL; ACETONITRILE; AMMONIUM ACETATE; AMYLOSE; DRUG METABOLITE; HYDROXYNORKETAMINE; KETAMINE; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG; NORKETAMINE;

ADULT; ARTICLE; BLOOD SAMPLING; CHIRALITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG RETENTION; DRUG URINE LEVEL; ELUTION; ENANTIOMER; FECES ANALYSIS; FREEZE THAWING; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LOW DRUG DOSE; MALE; MULTIPLE REACTION MONITORING; NORMAL HUMAN; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETENTION TIME; SENSITIVITY ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY; URINE SAMPLING; ANALOGS AND DERIVATIVES; CHEMISTRY; FECES; METABOLISM; PROCEDURES; STEREOISOMERISM;

ADULT; CHROMATOGRAPHY, LIQUID; FECES; HUMANS; KETAMINE; MALE; PILOT PROJECTS; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 85014508487     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2017.02.035     Document Type: Article

References (37)

1. [1] Klepstad, P., Maurset, A., Moberg, E.R., Oye, I., Evidence of a role for NMDA receptors in pain perception. Eur. J. Pharmacol. 187 (1990), 513–518.
2. [2] Oye, I., Paulsen, O., Maurset, A., Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260 (1992), 1209–1213.
3. [3] Turfus, S.C., Parkin, M.C., Cowan, D.A., Halket, J.M., Smith, N.W., Braithwaite, R.A., Elliot, S.P., Steventon, G.B., Kicman, A.T., Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos. 37 (2009), 1769–1778.
4. [4] Adams, J.D. Jr., Baillie, T.A., Trevor, A.J., Castagnoli, N. Jr., Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed. Mass Spectrom. 8 (1981), 527–538.
5. [5] Marietta, M.P., Way, W.L., Castagnoli, N. Jr., Trevor, A.J., On the pharmacology of the ketamine enantiomorphs in the rat. J. Pharmacol. Exp. Ther. 202 (1977), 157–165.
6. [6] White, P.F., Schuttler, J., Shafer, A., Stanski, D.R., Horai, Y., Trevor, A.J., Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br. J. Anaesth. 57 (1985), 197–203.
7. [7] Reich, D.L., Silvay, G., Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36 (1989), 186–197.
8. [8] Marchetti, F., Coutaux, A., Bellanger, A., Magneux, C., Bourgeois, P., Mion, G., Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5-year study of 51 patients. Eur. J. Pain 19 (2015), 984–993.
9. [9] Blonk, M.I., Koder, B.G., van den Bemt, P.M., Huygen, F.J., Use of oral ketamine in chronic pain management: a review. Eur. J. Pain 14 (2010), 466–472.
10. [10] Irwin, S.A., Iglewicz, A., Nelesen, R.A., Lo, J.Y., Carr, C.H., Romero, S.D., Lloyd, L.S., Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J. Palliat. Med. 16 (2013), 958–965.
11. [11] Irwin, S.A., Iglewicz, A., Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J. Palliat. Med. 13 (2010), 903–908.
12. [12] Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., Alkondon, M., Yuan, P., Pribut, H.J., Singh, N.S., Dossou, K.S., Fang, Y., Huang, X.P., Mayo, C.L., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., Thomas, C.J., Zarate, C.A. Jr., Gould, T.D., NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
13. [13] Singh, N.S., Zarate, C.A. Jr., Moaddel, R., Bernier, M., Wainer, I.W., What is hydroxynorketamine and what can it bring to neurotherapeutics?. Expert Rev. Neurother. 14 (2014), 1239–1242.
14. [14] Delatour, P., Jaussaud, P., Courtot, D., Fau, D., Enantioselective N-demethylation of ketamine in the horse. J. Vet. Pharmacol. Ther. 14 (1991), 209–212.
15. [15] Geisslinger, G., Menzel-Soglowek, S., Kamp, H.D., Brune, K., Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma. J. Chromatogr. 568 (1991), 165–176.
16. [16] Svensson, J.O., Gustafsson, L.L., Determination of ketamine and norketamine enantiomers in plasma by solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 678 (1996), 373–376.
17. [17] Geisslinger, G., Hering, W., Thomann, P., Knoll, R., Kamp, H.D., Brune, K., Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br. J. Anaesth. 70 (1993), 666–671.
18. [18] Hartvig, P., Valtysson, J., Lindner, K.J., Kristensen, J., Karlsten, R., Gustafsson, L.L., Persson, J., Svensson, J.O., Oye, I., Antoni, G., Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin. Pharmacol. Ther. 58 (1995), 165–173.
19. [19] Yanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Aoyama, T., Yamamura, Y., Iga, T., Stereoselective high-performance liquid chromatographic determination of ketamine and its active metabolite, norketamine, in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 746 (2000), 227–231.
20. [20] Chang, T., Glazko, A.J., A gas chromatographic assay for ketamine in human plasma. Anesthesiology 36 (1972), 401–404.
21. [21] Wieber, J., Gugler, R., Hengstmann, J.H., Dengler, H.J., Pharmacokinetics of ketamine in man. Anaesthesist 24 (1975), 260–263.
22. [22] Williams, M.L., Mager, D.E., Parenteau, H., Gudi, G., Tracy, T.S., Mulheran, M., Wainer, I.W., Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos. 32 (2004), 786–793.
23. [23] Davisson, J.N., Rapid gas chromatographic analysis of plasma levels of ketamine and major metabolites employing either nitrogen selective or mass spectroscopic detection. J. Chromatogr. 146 (1978), 344–349.
24. [24] Lian, K., Zhang, P., Niu, L., Bi, S., Liu, S., Jiang, L., Kang, W., A novel derivatization approach for determination of ketamine in urine and plasma by gas chromatography-mass spectrometry. J. Chromatogr. A 1264 (2012), 104–109.
25. [25] Theurillat, R., Knobloch, M., Levionnois, O., Larenza, P., Mevissen, M., Thormann, W., Characterization of the stereoselective biotransformation of ketamine to norketamine via determination of their enantiomers in equine plasma by capillary electrophoresis. Electrophoresis 26 (2005), 3942–3951.
26. [26] Theurillat, R., Knobloch, M., Schmitz, A., Lassahn, P.G., Mevissen, M., Thormann, W., Enantioselective analysis of ketamine and its metabolites in equine plasma and urine by CE with multiple isomer sulfated beta-CD. Electrophoresis 28 (2007), 2748–2757.
27. [27] Schmitz, A., Theurillat, R., Lassahn, P.G., Mevissen, M., Thormann, W., CE provides evidence of the stereoselective hydroxylation of norketamine in equines. Electrophoresis 30 (2009), 2912–2921.
28. [28] Theurillat, R., Larenza, M.P., Feige, K., Bettschart-Wolfensberger, R., Thormann, W., Development of a method for analysis of ketamine and norketamine enantiomers in equine brain and cerebrospinal fluid by capillary electrophoresis. Electrophoresis 35 (2014), 2863–2869.
29. [29] LeGrand, T., Roy, S., Monchaud, C., Grondin, C., Duval, M., Jacqz-Aigrain, E., Determination of ketamine and norketamine in plasma by micro-liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 48 (2008), 171–176.
30. [30] Moaddel, R., Venkata, S.L., Tanga, M.J., Bupp, J.E., Green, C.E., Iyer, L., Furimsky, A., Goldberg, M.E., Torjman, M.C., Wainer, I.W., A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta 82 (2010), 1892–1904.
31. [31] Rodriguez Rosas, M.E., Patel, S., Wainer, I.W., Determination of the enantiomers of ketamine and norketamine in human plasma by enantioselective liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 794 (2003), 99–108.
32. [32] Wang, K.C., Shih, T.S., Cheng, S.G., Use of SPE and LC/TIS/MS/MS for rapid detection and quantitation of ketamine and its metabolite, norketamine, in urine. Forensic Sci. Int. 147 (2005), 81–88.
33. [33] Zhao, X., Venkata, S.L., Moaddel, R., Luckenbaugh, D.A., Brutsche, N.E., Ibrahim, L., Zarate, C.A. Jr., Mager, D.E., Wainer, I.W., Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br. J. Clin. Pharmacol. 74 (2012), 304–314.
34. [34] Goldberg, M.E., Torjman, M.C., Schwartzman, R.J., Mager, D.E., Wainer, I.W., Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality 23 (2011), 138–143.
35. [35] European Medicines Agency (EMA) and Committee for Medicinal Products for Human Use (CHMP), Guideline on Bioanalytical Method Validation. 2013, FDA Ref Type: Online Source.
36. [36] Food and Drug Administration (FDA), Guidance for Industry—Bioanalytical Method Validation. 2013, FDA Ref Type: Online Source.
37. [37] Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., Alkondon, M., Yuan, P., Pribut, H.J., Singh, N.S., Dossou, K.S., Fang, Y., Huang, X.P., Mayo, C.L., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., Thomas, C.J., Zarate, C.A. Jr., Gould, T.D., NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.